Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases

Zalupski M(1988)Ifosfamide J Natl Cancer Inst 80 556-566

Baker LH(2009)Central and peripheral nervous system toxicity of common chemotherapeutic agents Cancer Chemother Pharmacol 63 761-767

Sioka C(1999)Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats J Pharmacol Exp Ther 289 820-824

Kyritsis AP(2005)Evaluating risk factors for the development of ifosfamide encephalopathy Am J Oncol 28 277-280

Visarius TM(2015)An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center J Oncol Pharm Pract 21 188-193

Stucki JW(2016)Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis J Formos Med Assoc 115 744-751

Lauterburg BH(2017)Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients Bull Cancer 104 208-212

David KA(2017)Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database PLoS One 12 e0182045-11

Picus J(2018)Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database SAGE Open Med 6 1-307

Szabatura AH(2016)On determining the most appropriate test cut-off value: the case of tests with continuous results Biochem Med 26 297-436

Zalupski M(1988)Ifosfamide J Natl Cancer Inst 80 556-566

Baker LH(2009)Central and peripheral nervous system toxicity of common chemotherapeutic agents Cancer Chemother Pharmacol 63 761-767

Sioka C(1999)Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats J Pharmacol Exp Ther 289 820-824

Kyritsis AP(2005)Evaluating risk factors for the development of ifosfamide encephalopathy Am J Oncol 28 277-280

Visarius TM(2015)An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center J Oncol Pharm Pract 21 188-193

Stucki JW(2016)Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis J Formos Med Assoc 115 744-751

Lauterburg BH(2017)Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients Bull Cancer 104 208-212

David KA(2017)Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database PLoS One 12 e0182045-11

Picus J(2018)Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database SAGE Open Med 6 1-307

Szabatura AH(2016)On determining the most appropriate test cut-off value: the case of tests with continuous results Biochem Med 26 297-436